30 DAFTAR PUSTAKA
1. Francis GS, Gassler JP, Sonnenblick EH. Pathophysiology and Diagnosis of Heart Failure. In: Fusler V, Alexander RW, O’Rourke RA (ed). The Heart 10th edition. 2005;1:655-685.
2. Colucci WS. Nesiritide for the treatment of decompensated heart failure. J Card Fail. 2001;7(1):92-100.
3. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;119:393-475.
4. Levy D, Kenchaiah, Larson MG, et al. Long term Trends in the incidence and Survival; with Heart Failure. N Engl J Med. 2002;347:1397-1402.
5. Hoobs FDR, Davis RC, Roalfe AK, et al. Reliability of N-Terminal Pro-Brain Natriuretic Peptide Assay in Diagnosis of Heart Failure: Cohort Study in Representative and High Risk Community Population. BMJ. 2002;324:1498-1502.
6. The European Society of Cardiology. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012. European Heart Journal. 2012;33:1787-1847.
7. Mukoyama M, Nakao K, Saito Y, et al. Increase Human Brain Natriuretic Peptide in Congestive Heart Failure. N Engl J Med. 1990;323:757-758.
8. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure. European Society of Cardiology. Guidelines for the Diagnosis and Treatment of Chronic Heart Failure. European Heart J. 2001;22:1527-1560.
9. Hartmann F, Packer M, Coats AJ, et al. Prognostic Impact of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial. Circulation. 2004;110:1780-1786.
10. Fonarow GC, Peacock WF, Phillips CO, et al. Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure. J Am Coll Cardiol. 2007;49:1943–1950
11. Van Kimmenade RR, Januzzi JL. Red cell distribution width measurement: what role does it have in heart failure?. Rev Esp Cardiol. 2012;65(7):593-594
12. Felker GM, Allen LA, Pocock SJ, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol. 2007;50:40–47.
13. Jackson CE, Dalzell JR, Bezlyak V, et al. Red cell distribution width has incremental prognostic value to B-type natriuretic peptide in acute heart failure. Eur J Heart Fail. 2009;11:1152–1154.
31 14. Al-Najjar Y, Goode KM, Zhang J, Cleland JG, Clark AL. Red cell distribution width: an inexpensive and powerful prognostic marker in heart failure. Eur J Heart Fail. 2009;11:1155–1162.
15. Constantino BT. The red cell histogram and the dimorphic red cell population. Labmedicine. 2011;42:300-308
16. Turgeon ML. Clinical hematology theory and procedures. Fifth edition. Philadelphia: Lippincott Williams & Wilkins, a Wolters Kluwer Business. 2012;103-104,543-544
17. Ciesla B. Hematology in practice. Philadelphia: FA Davis Company. 2007;22-26
18. Hammarsten O, Jacobsson S, Fu M. Red cell distribution width in chronic heart failure: a new independent marker for prognosis?. Eur J Heart Fail. 2010;12:213-214
19. Marks PW. Anemia: clinical approach. Dalam: Schmaier AH, Lazarus HM, penyunting. Concise guide to hamatology. Oxford: Wiley-blackwell. 2012;30
20. Suryaatmadja, M. Perkembangan Terkini B-type Natriuretic Peptide (BNP) Petanda Biokimia Gagal Jantung. Dalam: Suryaatmadja, M. (ed.) Pendidikan Berkesinambungan Patologi Klinik. 2004. Jakarta: Departemen Patologi Klinik FK UI. 2004:157-171.
21. de Lemos JA, McGuire D.K, Drazner M.H. B-Type Natriuretic Peptide in Cardiovascular Disease. The Lancet. 2003;362:316-322.
22. Hall C. Essential Biochemistry and Physiology of (NT-pro) BNP. Eur J Heart Fail. 2004;6:257-260
23. Kragelund C, Grønning B, Kober L, Hildebrandt P, Steffensen R. N-Terminal pro-B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart Disease. N Engl J Med. 2005;352(7): 666-675
24. Clerico A, Emdin M. Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: a Review. Clinical Chemistry. 2004;50:33-50.
25. Apple FS, Panteghini M, Ravkilde J, et al. Quality Specifications for B-type Natriuretic Peptide Assays. Clinical Chemistry. 2005;51:486-493.
26. Talwar S, Squire I.B, Downie P.F, Davies J.E, Ng L.L. Plasma N terminal Pro-Brain Natriuretic Peptide and Cardiotrophin 1 are Raised in Unstable Angina. Heart 2000;84:421–424.
27. Choi EY, Kwon HM, Yoon YW, Kim D, Kim HS. Assessment of Extent of Myocardial Ischemia in Patients with Non-ST Elevation Acute Coronary Syndrome Using Serum B-Type Natriuretic Peptide Level. Yonsei Med J. 2004;45(2):255-262.
28. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Nielsen B. Increased Cardiac BNP Expression Associated with Myocardial Ischemia. FASEB J. 2003;17:1105-1107.
32 29. Anwaruddin S, Llyod-Jones DM, Baggish A, et al. Renal function, Congestive Heart Failure and Aminoterminal pro-brain Natriuretic Peptide Measurement: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47:91-97
30. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41(3):571-579.
31. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339(5):321-328.
32. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnand R, et al. Clinical application of B-type natriuretic peptide (BNP) testing. Eur J Heart Fail. 2003;24(19):1710–1718.
33. Douglas, P.S. The Left Atrium. A Biomarker of Chronic Diastolic Dysfunction and Cardiovascular Disease Risk. J Am Coll Cardiol. 2003;42:1206-1207.
34. Jackson G, Gibbs CR, Davies MK, Lip GYH. ABC of Heart Failure: Pathophysiology. BMJ. 2000;320:167-170.
35. Bonaque JC, Pascual-Figal DA, Manzano-Fernández S, et al. El ancho de distribución eritrocitaria aporta valor pronóstico adicional en pacientes ambulatorios con insuficiencia cardiac crónica. Rev Esp Cardiol. 2012;65:606–612.
36. Van Kimmenade RRJ, Mohammed AA, Uthamalingam S, et al. Red blood cell distribution width and one-year mortality in acute heart failure. Eur J Heart Fail. 2010;12:129–136.
37. Förhécz Z, Gombos T, Borgulya G, Pozsonyi Z, Prohászka Z, Jánoskuti L. Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. Am Heart J. 2009;158:659–666.
38. Allen LA, Felker GM, Mehra MR, et al. Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. J Card Fail. 2010;16:230–238.
39. O’Brien TX. Iron metabolisme, anemia, and heart failure. J Am Coll Cardiol. 2011; 58:1252-1253.
40. Okonko DO, Mandal AKJ, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relations to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58:1241–1251.
41. Pemberton CJ, Yandle TG, Rademaker MT, Charles CJ, Aitken GD, Espiner EA. Amino-terminal proBNP in ovine plasma: evidence for enhanced secretion in response to cardiac overload. American Journal of Physiology - Heart and Circulatory Physiology. 1998;275:1200-1208.
33 42. Januzzi JL, Kimmenade RV, Lainchbury J, et.al. NT-proBNP Testing for Diagnosis of Short-term Prognosis in Acute Destabilized Heart Failure: an International Pooled Analysis of 1256 Patient. European Heart Journal. 2006;27:330-337.
43. Hebl V, Zakhrova MY, Canoniero M, Duprez D, Garcia S. Correlation of Natriuretic Peptides and Inferior Vena Cava Size in Patient with Congestion Heart Failure. Vascular Health Risk Management. 2012;8:213-218.
44. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-Terminal Pro-Brain Natriuretic Peptide and Adrenomedullin: New Neurohormonal Predictors of Left Ventricular Function and Prognosis after Myocardial Infarction. Circulation. 1998;97:1921-1929.
45. de Derus S, Pharand C, Williamson DR. Brain Natriuretic Peptide in the Management of Heart Failure. The Versatile Neurohormone. Chest. 2004;125:652-668.
46. Celic A, Kok F, Kadi H. Relationship between red cell distribution width and echocardiographic parameters in patients with diastolic heart failure. Kaohsiung Journal of Medical Sciences. 2012;28:165-172.
47. Patel KV, Ferrucci L, Ershler BW, Longo DL, Guralnik JM. Red Cell Distribution Width and the Risk of Death in Middle-aged and Older Adults. Arch Intern Med. 2009;169(5):515-523.
48. Sastroasmoro Sudigdo, Ismael Sofyan. Dasar-dasar Metodologi Penelitian Klinis. Edisi ke-2. Jakarta: Sagung Seto. 2002;280.
